Drug Approval | May 18, 2022
Themis Medicare gets add on approval for Viralex
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
Viralex (Inosine Pranobex) is an immunomodulatory agent with broad-spectrum antiviral properties
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
OxemiaTM (Desidustat) is an oral tablet formulation that is the first-in-India alternative to injectable erythropoietin-stimulating agents (ESAs)
Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections
The drug is priced at Rs 2000 for a course of 40 tablets
It has also been granted permission to conduct trials for booster dose
A toll-free helpline to be set up to help doctors and patients
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The recommendation was made by the Indian SARS-CoV-2 Genomics Sequencing Consortium (INSACOG), a network of national testing labs set up by the government to monitor genomic variations of Covid-19
The UK’s Medicine and Healthcare products Regulatory Agency has already approved the booster dose of AstraZenenca’s Covid-19 vaccine, which is administered in India
Subscribe To Our Newsletter & Stay Updated
